Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 2, 2020

Life Arc invests £1m in University of Cambridge spin-out PolyProx

By Allie Nawrat

University of Cambridge Department of Pharmacology spin-out PolyProx Therapeutics has received £1m in seed capital from translation-focused medical research charity Life Arc. The funding will be provided through the charity’s £25m seed fund.

This follows the £3.4m that PolyProx raised in seed capital in April 2019. This financing round was led by both Cambridge Innovation Capital, RT Capital and Cambridge Enterprise.

All of this funding is being used to continue to develop the company’s polyproxin molecules as a new cancer treatment.

Polyproxin molecules are developed using PolyProx’s platform, which focuses on harnessing proteostasis networks to manipulate protein stability and therefore the growth of tumours.

PolyProx’s molecules can therefore leverage a cell’s natural degradation machineries to target and remove disease-causing proteins, which halts the growth of the tumour.

Initially, PolyProx wants to focus on developing polyproxin drugs against aberrant proteins and tumour types, which small molecule drugs and monoclonal antibodies have struggled to tackle to date.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

As a result of this funding, Life Arc Seed fund investment principal of the fund Enrique Millan will sit on PolyProx’s board.

Millan commented: “LifeArc’s Seed Fund was established to help translate promising medical research into patient benefit.

“We are excited to be working with the PolyProx team on the development of a novel, first-in-class therapeutic modality that could potentially address some of the challenges in cancer treatment.”

PolyProx executive chairman Andrew Sandham added: “We are delighted to welcome LifeArc as an investor which enables us to expand our drug discovery resources following our recent move to new laboratories in Cambridge.

“We have made exciting progress on our polyproxin drug discovery projects in oncology and look forward to sharing proof of concept data with prospective investors and partners later this year.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy